Featured Research

from universities, journals, and other organizations

Dual-Acting Topical Gel May Stop Acne Breakouts

Date:
November 29, 2006
Source:
University Of Cincinnati
Summary:
University of Cincinnati (UC) dermatologists are testing a new topical gel designed to reduce abnormal clogging of the pores while simultaneously fighting off certain bacterial infections linked to severe acne development.

Pranav Sheth, MD, examines a patient for acne.
Credit: Image courtesy of University Of Cincinnati

University of Cincinnati (UC) dermatologists are testing a new topical gel designed to reduce abnormal clogging of the pores while simultaneously fighting off certain bacterial infections linked to severe acne development.

Led locally by Pranav Sheth, MD, and Debra Breneman, MD, this multi-center, phase-3 trial will determine whether the dual-acting topical gel is more effective than the single medications physicians currently prescribe for acne prevention.

The investigational drug is a combination of the retinoid adapalene, a vitamin A--like compound that has been shown to reduce the formation of comedone (clogged pores) and inflammation, and the strong antibacterial agent benzoyl peroxide. Both medications are currently approved by the U.S. Food and Drug Administration for the treatment of acne, but they are prescribed as single agents--not a combined therapy.

Although the exact cause of acne is unknown, scientists believe genetics, hormones, oil production and diet all play a role. These factors, as Sheth explains, combine to clog the pores, allow excessive bacteria growth and produce the inflammation that causes acne.

"This new gel was designed to suppress the factors that lead to acne development," says Sheth, assistant professor of dermatology at UC. "Currently, patients are given several separate topical agents with different mechanisms of action to create the desired effect on acne.

"By combining the two medications into one treatment gel," he adds, "we hope to produce a convenient product that the patient is more likely to use but also yields better results than current individual therapies."

Researchers are currently recruiting about 40 individuals aged 12 or older who have been diagnosed with severe acne. Study participants will be randomized into four treatment groups who will receive the experimental combination drug, adapalene topical gel only, benzoyl peroxide gel only or a placebo.

Participants will apply the gel to their faces every evening for 12 weeks, keeping a log of any moisturizers, sunscreens or other topical creams they have applied. Researchers will track acne changes every one to four weeks during follow-up examinations. Once treatment is complete, study participants will complete several brief surveys on quality-of-life issues related to acne and the trial gel's effectiveness in alleviating their acne.

Study participants will be compensated for their time and receive study-related visits, procedures and drugs at no cost. For trial enrollment information, call Vivian Berger at (513) 475-7575.

This trial is sponsored by Galderma USA, maker of the investigational gel. Sheth and Breneman have no financial interests in the company.


Story Source:

The above story is based on materials provided by University Of Cincinnati. Note: Materials may be edited for content and length.


Cite This Page:

University Of Cincinnati. "Dual-Acting Topical Gel May Stop Acne Breakouts." ScienceDaily. ScienceDaily, 29 November 2006. <www.sciencedaily.com/releases/2006/11/061129092428.htm>.
University Of Cincinnati. (2006, November 29). Dual-Acting Topical Gel May Stop Acne Breakouts. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2006/11/061129092428.htm
University Of Cincinnati. "Dual-Acting Topical Gel May Stop Acne Breakouts." ScienceDaily. www.sciencedaily.com/releases/2006/11/061129092428.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
Too Few Teens Receiving HPV Vaccination, CDC Says

Too Few Teens Receiving HPV Vaccination, CDC Says

Newsy (July 24, 2014) The Centers for Disease Control and Prevention is blaming doctors for the low number of children being vaccinated for HPV. Video provided by Newsy
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins